DEEP RESEARCH · BIOPLUS

BioPlus: MDM Crosslinking Technology and Vertical Integration as a Bio-Platform Strategy

From HA filler cash cow to GLP-1, toxin, and DDS platform expansion

Date: 2025-12-17 · Aesthetic medical-device and bio-platform analysis · Naver Blog

0. Bottom line first

Official fact: The source presents cumulative 3Q25 revenue of KRW 67.7 billion, operating profit of KRW 14.0 billion, and an operating margin of about 20%. Historical operating margins had approached 40-50%, but were adjusted by distribution restructuring and new-business investment.

Interpretation: Reducing low-margin ODM, strengthening direct/branded sales, launching Bonyx, GLP-1 R&D, and global marketing costs weigh on short-term earnings, but can be read as a transition toward higher-quality revenue and more brand control.

1. Corporate DNA: the contrarian DVS bet

BioPlus began in 2003 as Human Tissue Korea, focused on tissue engineering and human tissue graft materials. The decisive pivot came when BDDE was the standard HA filler crosslinker and BioPlus chose DVS instead. DVS can form stronger, more rigid bonds, but its high reactivity makes residual removal difficult.

Official fact: The source says BioPlus built MDAP™, a multi-step purification technology to remove residual DVS toxicity, and the broader MDM® Technology platform after years of R&D. It received KFDA product approval in 2014.

Interpretation: This pivot changed the company identity from generic manufacturing to material-science technology. CEO Jung Hyun-kyu’s philosophy also favors differentiated physical properties, such as viscoelasticity and moldability, over celebrity-driven advertising.

2. Business model and global strategy

BioPlus is migrating from ODM toward branded direct sales and private-label contracts with large global partners. About 72% of revenue comes from overseas markets, reflecting a choice to avoid intense domestic price competition and maximize profitability where premium pricing works.

Official fact: The Hainan project uses a local factory and Class II medical-device production/sales approval instead of simply waiting for NMPA import approval. The source mentions GMP certification for the Hainan plant in March 2025.

For the U.S., BioPlus established BioPlus USA Inc. in 3Q25 to directly manage FDA clinical and approval processes and prepare a sales network. For South America, especially Brazil, the source emphasizes demand for body contouring and fit with high-viscosity fillers.

3. MDM® technology moat

Interpretation: The lock-in described by the source is closer to physician injection feel than consumer brand awareness. Once physicians become used to high G-prime and moldability, moving back to thinner products becomes harder.

4. Capacity and vertical integration

Official fact: BioPlus invested about KRW 160 billion to build the Eumseong Bio-Complex in Chungbuk. The source says the 2025 completion and ramp-up enable annual capacity for 36 million botulinum-toxin vials, 40 million obesity-treatment units, and 40 million filler syringes.

Subsidiary Infinita produces prefilled syringes and related materials, reducing external dependence and improving quality-control consistency. The acquisition of a 52.96% stake in Ubiprotain is presented as capital allocation that secures protein-recombination technology for botulinum toxin and GLP-1 obesity treatments.

5. Financials and cash flow

2024-2025 was the peak CAPEX period for Eumseong construction. The source argues this hurt near-term free cash flow, but once major investment ends from 2026, operating leverage may emerge despite depreciation.

• Margin decline drivers: ODM reduction, direct-sales transition, Bonyx launch, obesity-treatment R&D, and higher global marketing costs.
• Cash-flow gap: Net income is positive, but OCF tends to be lower or negative, with accounts receivable and inventories cited as the cause.
• Financing: CB proceeds were used for production facilities such as the Eumseong plant rather than operating expenses, which the source frames as “good debt.”

6. Scenarios and risks

Bull Case

• MDM technology acts as a hard-to-copy moat and supports excess returns.
• Eumseong Bio-Complex operation removes supply constraints and lifts revenue scale.
• If GLP-1 pipelines such as liraglutide generics and semaglutide microneedle patches produce clinical progress, the source argues the valuation could rerate from medical-device multiples to biopharma multiples.

Bear Case

• If China NMPA or U.S. FDA approval is delayed, Eumseong depreciation can weigh on earnings.
• Slow conversion of inventories and receivables into cash can create additional financing or liquidity pressure.
• If major regulators raise new safety issues around DVS crosslinkers, the company’s core MDM technology base could be challenged.